Glp-1 Therapy In Rare Genetic Disorders

A new worm model developed by Brown University researchers could play a key role in treating a rare genetic disease that causes paralysis in children and worsens with age.GLP-1 drugs may reshape how brain values rewarding foods.

gene therapy stem cell transplant child health rare disease brain tumor. When 13-month-old Adams stem cell transplant failed, doctors presented his parents with two grim options: a second transplant with a 10% to 15% risk of death, or an untested gene therapy.

Keywords: UBA5 disorder, gene therapy, UFMylation, developmental and epileptic encephalopathy, neurogenetics, rare genetic diseases, viral vectors, adeno-associated virus, molecular mechanisms, translational medicine, pediatric neurology, genomic medicine.

Fractyl Health has received Clinical Trial Application authorisation in the Netherlands to initiate the Phase I/II first-in-human study of RJVA-001, the first clinical candidate from the companys Rejuva Smart GLP-1 gene therapy platform.

From custom gene editing to a discovery that could help stop pancreatic cancer before it starts, these advances offer a glimpse at the future of human health.They designed a custom gene for a single patient, a baby boy born with a rare genetic and life-threatening metabolic disorder.

All of the five therapeutic GLP-1RAs, currently approved for therapy of type 2 diabetes, are peptide molecules, which are administered in subcutaneous injections.

GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease.